Latest Systemic lupus erythematosus Stories
HERZLIYA, Israel, March 25, 2014 /PRNewswire/ -- XTL Biopharmaceuticals Ltd. (NASDAQ: XTLB, TASE: XTL) ("XTL" or the "Company"),
LFA-REAL(TM) System is first of its kind tool to bring patients deeply into the development process WASHINGTON, March 20, 2014 /PRNewswire-USNewswire/ -- The Lupus Foundation of America
Discounted research study “PharmaPoint: Systemic Lupus Erythematosus and Lupus Nephritis - Global Drug Forecast and Market Analysis to 2022” elaborated by GlobalData is now available at MarketPublishers.com.
--Novel Biologic Targets Innovative New Mechanism in Lupus-- SEATTLE, March 17, 2014 /PRNewswire/ -- Resolve Therapeutics, LLC announced today the initiation of clinical studies with
HAYWARD, Calif., March 12, 2014 /PRNewswire/ -- Anthera Pharmaceuticals, Inc.
Achieve is conducting a phase II, placebo-controlled, multi dose, 24-week clinical study to evaluate the efficacy and safety of a new autoimmune medication in participants living with
The new “Autoimmune Disease Treatment” writing on the website Vkool.com covers natural ways to treat autoimmune diseases effectively. Seattle, Wa (PRWEB)
Lupus Research Organizations Welcome Big-Science Push to Drive New Therapies for Lupus Patients NEW YORK, Feb.
Lupus Foundation of America Joins a Five-Year Initiative to Bring Together Government, Academia, Industry and Nonprofit Health Organizations to Harness Capabilities and Resources
HAYWARD, Calif., Jan. 30, 2014 /PRNewswire/ -- Anthera Pharmaceuticals, Inc.
- An imitative word; an onomatopoetic word.